These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
781 related articles for article (PubMed ID: 33634012)
41. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209 [TBL] [Abstract][Full Text] [Related]
42. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. Yang H; Zhou X; Sun L; Mao Y Front Oncol; 2019; 9():47. PubMed ID: 30891423 [No Abstract] [Full Text] [Related]
43. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. Shi T; Zhu S; Guo H; Li X; Zhao S; Wang Y; Lei X; Huang D; Peng L; Li Z; Xu S Front Oncol; 2021; 11():567978. PubMed ID: 33708622 [TBL] [Abstract][Full Text] [Related]
44. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153 [TBL] [Abstract][Full Text] [Related]
45. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes. Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883 [TBL] [Abstract][Full Text] [Related]
46. The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis. Huang P; Hu W; Zhu Y; Wu Y; Lin H Front Oncol; 2020; 10():626932. PubMed ID: 33718120 [TBL] [Abstract][Full Text] [Related]
47. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis. Yang L; Xue R; Pan C Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869 [No Abstract] [Full Text] [Related]
48. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. Ji Y; Wang H World J Surg Oncol; 2020 Aug; 18(1):197. PubMed ID: 32767977 [TBL] [Abstract][Full Text] [Related]
49. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984 [TBL] [Abstract][Full Text] [Related]
50. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L Front Pharmacol; 2019; 10():139. PubMed ID: 30873025 [No Abstract] [Full Text] [Related]
51. The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis. Li P; Zhong Y; Zhang M; Zheng Y; Peng W Transl Cancer Res; 2024 Aug; 13(8):3944-3959. PubMed ID: 39262473 [TBL] [Abstract][Full Text] [Related]
52. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y Front Oncol; 2019; 9():897. PubMed ID: 31620360 [No Abstract] [Full Text] [Related]
53. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. Pan ZK; Ye F; Wu X; An HX; Wu JX J Thorac Dis; 2015 Mar; 7(3):462-70. PubMed ID: 25922726 [TBL] [Abstract][Full Text] [Related]
54. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302 [TBL] [Abstract][Full Text] [Related]
55. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Kim J; Kim S; Lee HS; Yang W; Cho H; Chay DB; Cho SJ; Hong S; Kim JH Gynecol Oncol; 2018 May; 149(2):381-387. PubMed ID: 29572029 [TBL] [Abstract][Full Text] [Related]
56. Association of Tumor Size With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients. Jin X; Shen C; Yang X; Yu Y; Wang J; Che X Front Oncol; 2022; 12():881850. PubMed ID: 35719999 [TBL] [Abstract][Full Text] [Related]
57. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. Qiu Y; Jiang J; Zhang M; Qin Y Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485 [TBL] [Abstract][Full Text] [Related]
58. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis. Wan B; Deng P; Dai W; Wang P; Dong Z; Yang C; Tian J; Hu T; Yan K Medicine (Baltimore); 2021 Apr; 100(14):e25315. PubMed ID: 33832105 [TBL] [Abstract][Full Text] [Related]
59. Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis. Fu H; Fu Z; Mao M; Si L; Bai J; Wang Q; Guo R Crit Rev Oncol Hematol; 2023 Sep; 189():104084. PubMed ID: 37536446 [TBL] [Abstract][Full Text] [Related]
60. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis. Qin Y; Luan J; Zhou X; Li Y Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]